CA2235487A1 - Solubilisation methods - Google Patents

Solubilisation methods Download PDF

Info

Publication number
CA2235487A1
CA2235487A1 CA002235487A CA2235487A CA2235487A1 CA 2235487 A1 CA2235487 A1 CA 2235487A1 CA 002235487 A CA002235487 A CA 002235487A CA 2235487 A CA2235487 A CA 2235487A CA 2235487 A1 CA2235487 A1 CA 2235487A1
Authority
CA
Canada
Prior art keywords
agent
amphiphile
solulan
medicament
common solvent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002235487A
Other languages
English (en)
French (fr)
Inventor
Roger Randal Charles New
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cortecs Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2235487A1 publication Critical patent/CA2235487A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
CA002235487A 1995-10-25 1996-10-25 Solubilisation methods Abandoned CA2235487A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9521805.3A GB9521805D0 (en) 1995-10-25 1995-10-25 Solubilisation methods
GB9521805.3 1995-10-25

Publications (1)

Publication Number Publication Date
CA2235487A1 true CA2235487A1 (en) 1997-05-01

Family

ID=10782854

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002235487A Abandoned CA2235487A1 (en) 1995-10-25 1996-10-25 Solubilisation methods

Country Status (12)

Country Link
EP (1) EP0857061A1 (ja)
JP (1) JP2000502990A (ja)
KR (1) KR19990067028A (ja)
CN (1) CN1202818A (ja)
AU (1) AU704292B2 (ja)
BR (1) BR9611343A (ja)
CA (1) CA2235487A1 (ja)
GB (1) GB9521805D0 (ja)
NO (1) NO981864L (ja)
NZ (1) NZ320442A (ja)
WO (1) WO1997015289A1 (ja)
ZA (1) ZA969016B (ja)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9605709D0 (en) * 1996-03-19 1996-05-22 Cortecs Ltd Method
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
EP2020990B1 (en) 2006-05-30 2010-09-22 Intarcia Therapeutics, Inc Two-piece, internal-channel osmotic delivery system flow modulator
EP2363112B8 (en) 2006-08-09 2018-11-21 Intarcia Therapeutics, Inc. Osmotic delivery systems and piston assemblies
MX2009011123A (es) 2007-04-23 2009-11-02 Intarcia Therapeutics Inc Formulaciones de suspensiones de peptidos insulinotropicos y sus usos.
DK2240155T3 (da) 2008-02-13 2012-09-17 Intarcia Therapeutics Inc Indretninger, formuleringer og fremgangsmåder til levering af flere gavnlige midler
MX352878B (es) 2009-09-28 2017-12-13 Intarcia Therapeutics Inc Establecimiento y/o terminacion rapidos de suministro de estado estable sustancial de farmaco.
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
MX2017015504A (es) 2015-06-03 2018-05-15 Intarcia Therapeutics Inc Sistemas de colocacion y remoción de implante.
WO2017200943A1 (en) 2016-05-16 2017-11-23 Intarcia Therapeutics, Inc. Glucagon-receptor selective polypeptides and methods of use thereof
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
IL307966A (en) 2017-01-03 2023-12-01 Intarcia Therapeutics Inc Methods involving continuous administration of a GLP-1 receptor agonist and co-administration of a drug

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0012115A1 (de) * 1978-12-04 1980-06-11 Ciba-Geigy Ag Pharmazeutische Präparate zur topischen Behandlung von Virusinfektionen
US4411882A (en) * 1978-12-21 1983-10-25 Sandoz Ltd. Galenical compositions

Also Published As

Publication number Publication date
WO1997015289A1 (en) 1997-05-01
KR19990067028A (ko) 1999-08-16
NO981864D0 (no) 1998-04-24
JP2000502990A (ja) 2000-03-14
ZA969016B (en) 1998-04-28
EP0857061A1 (en) 1998-08-12
GB9521805D0 (en) 1996-01-03
BR9611343A (pt) 1999-12-28
AU704292B2 (en) 1999-04-15
CN1202818A (zh) 1998-12-23
NO981864L (no) 1998-06-24
NZ320442A (en) 1999-10-28
AU7317896A (en) 1997-05-15

Similar Documents

Publication Publication Date Title
AU704292B2 (en) Solubilisation methods
Park et al. A new preparation method for protein loaded poly (D, L-lactic-co-glycolic acid) microspheres and protein release mechanism study
Viswanathan et al. Preparation of non-porous microspheres with high entrapment efficiency of proteins by a (water-in-oil)-in-oil emulsion technique
EP2040680B1 (en) Improvements relating to pharmaceutical compositions
AU722627B2 (en) Stable particle in liquid formulations
US6368619B1 (en) Hydrophobic preparations of hydrophilic species and process for their preparation
AU2002317409B2 (en) Aqueous dispersion comprising stable nanoparticles of a water-insoluble active and an excipient like middle chain triglycerides (MCT)
JP3267611B2 (ja) リポソーム−ポリエンプレリポソーム粉末とその製造方法
MXPA04009103A (es) Preparacion de nanodispersiones estabilizadas, esteriles.
Chaudhari et al. Nanostructured lipid carriers as a strategy for encapsulation of active plant constituents: Formulation and in vitro physicochemical characterizations
CN102151250A (zh) 一种固体脂质纳米粒制备新方法
Kamble et al. Norfloxacin mixed solvency based solid dispersions: An in-vitro and in-vivo investigation
KR930009897B1 (ko) 메틸하이드록시프로게스테론 아세테이트를 수팽윤성 수불용성 폴리머에 첨가하는 방법
EP1293248B1 (en) Novel calixarene based dispersible colloidal system in the form of nanoparticles
WO2001032218A1 (en) Compositions and methods for controlled-release delivery and increased potency of pharmaceuticals via hydrophobic ion-pairing
JP2007525474A (ja) ポリオキシエチレン誘導体のナノ粒子
AU714485B2 (en) Methods of preserving microorganisms
US6165773A (en) Methods of preserving viruses
JP2758297B2 (ja) リポソーム調製物
Soujanya et al. A Review on Novel Vesicular Drug Delivery System: Proniosomes.
CN110393711A (zh) 一种改善plga载多肽类药物微球中药物低包封和高初始突释问题的方法
CN102125565B (zh) 一种24-亚甲基环木菠萝醇阿魏酸酯的药物组合物
JP2550352B2 (ja) リポソ−ム製剤
CN117224481A (zh) 一种食品级的o/w槲皮素微乳及其制备方法和应用
Muthukumar Chapter-6 Solid Dispersion

Legal Events

Date Code Title Description
FZDE Discontinued